<DOC>
	<DOC>NCT03061955</DOC>
	<brief_summary>The objective of this study is to evaluate the safety and efficacy of concurrent administration of influenza vaccine in patients receiving anti-PD1 immunotherapy (nivolumab or pembrolizumab). This will be a prospective observational study, aiming to assess patient tolerance of treatment, adverse events (incidence, grade, need for hospitalization), incidence of influenza infections, and seroconversion rates.</brief_summary>
	<brief_title>Safety and Efficacy of Concurrent Administration of Influenza Vaccine in Patients Undergoing Anti-PD-1 Immunotherapy (Nivolumab, Pembrolizumab)</brief_title>
	<detailed_description />
	<mesh_term>Influenza, Human</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Pembrolizumab</mesh_term>
	<mesh_term>Nivolumab</mesh_term>
	<criteria>18 years or older Currently receiving immunotherapy with antiPD1 agents (Nivolumab or Pembrolizumab) Have not received influenza vaccination prior to study entry date for the upcoming flu season 20162017 No previous contraindication to receiving influenza vaccination Histologically proven cancer Expected lifetime of at least 12 weeks Previous cancer Autoimmune disease or immunosuppressive treatments Corticosteroid treatment Those who have a potential indication to change chemotherapy treatment in 42 days following start of treatment History of clinically or virologically confirmed influenza infection in the previous six months Previous contraindication to receiving influenza vaccination Previous allergic/adverse reaction with influenza vaccination Have received influenza vaccination prior to study entry date for upcoming 20162017 flu season Positive anti influenza antibody titers as determined by the baseline blood determination (day 0)</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>